

Compumedics aims at \$900m brain market

JUL 08 2015

Compumedics brain blood-flow Doppler ultrasonography division, **Compumedics Germany (DWL)**, has secured contracts totaling \$5m to supply Transcranial Doppler (TCD) systems to the German market.

\$CMP says DWL is moving from the current physiological TCD measurement market worth \$US30m for the 3D Transcranial Color Doppler into the brain imaging market valued at \$US900m.

Market response: Shares climb 18.5% to 32c.

The deal was announced as part of a targeted program, jointly coordinated by the **German-Australian Chamber of Industry and Commerce** and the **Australian Trade Commission**, headed by Australian Minister for Finance **Mathias Cormann** and **David Richie**, AO Australian Ambassador to Germany.

Compumedics DWL CEO **Christopher Witte**: "This tranche of deals opens the way to an enormous market opportunity comprising of the new generation 3D-Transcranial Color Doppler and Duplex devices with \$5m worth of business incrementally distributed over the next three years.

"The contracts also create a pathway to new and virtually untapped market fields that DWL has been investigating, like Traumatic Brain Injury, stroke and the investigation of other brain disease and disorders.

"These fields have been largely inaccessible due to the traditional complexity and difficulty in deploying ambulatory TCD systems.

"Importantly, this newly announced deal enhances the company's European market presence with short-term revenue increases being realized with the upcoming release of a range of products, including an advanced array of vivid color 3-DI graphic imaging."

Dr David Burton, Chairman/CEO, Compumedics

CMP Chairman/CEO **Dr David Burton**: "This government trade mission highlights the importance that such initiatives can have in terms of economic, business and trade confidence with principal trade partners such as Germany.

"Following today's announcement Compumedics' DWL has committed further investment into the German region and expects to significantly expand trade across all products sectors, including clinical sleep, neurology and research neurology sectors of its business."

http://www.medifydaily.com.au/compumedics-aims-at-900m-brain-market/